News

Early data for Ablynx molecule in psoriasis

Tuesday 31 January 2017
Country
Belgium

Early clinical data for a therapeutic protein developed by Ablnyx NV to treat patients with psoriasis has demonstrated that the treatment is safe, with some evidence of a reduction in disease activity. The treatment targets the interleukin-17 (IL-17) pathway.

J&J to pay $30 billion for Actelion

Thursday 26 January 2017
Country
Switzerland

Johnson & Johnson Inc is making an agreed offer to buy Actelion Ltd for $30 billion in a transaction that will have tax and portfolio benefits for it while providing money for the launch of a new Switzerland-based R&D start-up to be led by Actelion’s current management.

Novartis' profit margins remain under pressure

Wednesday 25 January 2017
Country
Switzerland

Novartis AG continued its programme of cutting costs and purchasing companies or products to bolster its pipeline in 2016, but this was not enough to stem an annual and fourth quarter decline in sales and operating profit. Moreover, little change is expected for 2017.

Ingmar Hoerr appointed advisor to European Commission

Friday 20 January 2017
Country
Germany

Ingmar Hoerr, chief executive of CureVac AG, has been appointed as one of 15 members of a new group that will advise the European Commission on strengthening the environment for research and innovation in the European Union.

Consultation on EU capital market reform

Friday 20 January 2017
Country
Belgium

A proposed liberalisation of rules that govern financial transactions in the European Union is the subject of a public consultation that started on 20 January and will continue until 17 March. The consultation is being managed by the European Commission.

Letter from the Editor: Innovation in the New Year

Tuesday 17 January 2017
Country
Belgium

(The following editorial appears in the January 2017 edition of MedNous) Yes, there are plenty of geopolitical risks going into 2017, but the biopharma industry is entering the New Year with plenty of cash and good prospects for innovation. In this issue we look at some recent developments.

Cross-consent accord for Charpentier IP

Saturday 14 January 2017
Country
Ireland

Four companies with rights to intellectual property (IP) generated by Emmanuelle Charpentier and colleagues for the gene editing technology CRISPR/Cas9 have reached an agreement under which rights to the technology given by one member of the group will mean consent from the others.

Immatics in bispecific deal with Amgen

Thursday 12 January 2017
Country
Germany

Germany-based Immatics Biotechnologies GmbH has secured its most significant collaboration to date with the signing of a research and licencing agreement with Amgen Inc to develop T cell engaging bispecific immunotherapies targeting multiple cancers.

Macrophage Pharma secures funding

Thursday 12 January 2017
Country
United Kingdom

Macrophage Pharma Ltd, a two-year old company set up to advance small molecule drugs targeting tumour-associated macrophages, has raised £9 million in Series A finance from specialist oncology investors.